Department of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Sklodowskiej-Curie Str. 9, 85-094 Bydgoszcz, Poland.
Department of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Sklodowskiej-Curie Str. 9, 85-094 Bydgoszcz, Poland.
Clin Res Hepatol Gastroenterol. 2021 May;45(3):101664. doi: 10.1016/j.clinre.2021.101664. Epub 2021 Mar 3.
Hepatocellular carcinoma (HCC) is the fourth most common cause of death among cancers. The poor prognosis of HCC might be caused by a population of cancer stem cells (CSC). CSC have similar characteristics to normal stem cells and are responsible for cancer recurrence, chemoresistance, radioresistance and metastasis. Liver cancer stem cells (LCSC) are identified via specific surface markers, such as CD44, CD90, CD133, and EpCAM (CD326). Recent studies suggested a complex interaction between mentioned LCSC markers and clinical features of HCC. A high expression of CSC is correlated with a negative prognostic factor after surgical resection of HCC and is connected with more aggressive tumor behavior. Moreover, LCSC might be responsible for increasing resistance to sorafenib, a kinase inhibitor drug. A reduction in the LCSC population may be crucial to successful advanced HCC therapy.
肝细胞癌（HCC）是癌症死亡的第四大常见原因。HCC 预后不良的原因可能是存在癌症干细胞（CSC）。CSC 具有与正常干细胞相似的特征，是导致癌症复发、化疗耐药、放疗耐药和转移的原因。肝癌干细胞（LCSC）通过特定的表面标志物如 CD44、CD90、CD133 和 EpCAM（CD326）来鉴定。最近的研究表明，LCSC 标志物与 HCC 的临床特征之间存在复杂的相互作用。CSC 的高表达与 HCC 手术后的负预后因素相关，并与更具侵袭性的肿瘤行为有关。此外，LCSC 可能导致索拉非尼（一种激酶抑制剂药物）耐药性增加。减少 LCSC 群体可能对成功治疗晚期 HCC 至关重要。
